What is BPC-157 used for?

BPC-157 is widely discussed in the wellness community for its recovery and tissue-support properties.

Yes — every batch comes with a third-party Certificate of Analysis viewable on this page.

Tendon, ligament & muscle recovery

Rat Achilles-transection, medial collateral ligament and quadriceps-crush models form the largest single literature cluster. Studies typically compare histological healing, tensile strength recovery and functional gait scores against saline controls over 14–30 day observation windows.

Gastrointestinal lining

Gastric ulcer, colitis, and short-bowel-syndrome rodent models examine mucosal integrity, cytokine response (TNF-α, IL-6) and restoration of barrier function.

Neurological & CNS models

A growing secondary literature covers traumatic brain injury, spinal cord contusion and neuro-inflammatory models in rodents.

Vascular & wound models

Full-thickness skin-wound, burn, and ischaemia-reperfusion studies in rats report on angiogenesis markers and closure-time endpoints.

Cardio-metabolic adjuncts

Smaller literature pools explore QT-prolonging-agent counter-regulation and hepatic-ischaemia models in rodents.

What should Canadian labs verify before comparing BPC-157 suppliers?

Use documentation, not outcome claims, as the comparison baseline: lot-matched COA, HPLC purity, mass confirmation, batch number, vial label, shipping conditions, and research-use-only framing. LynxLabs publishes the current COA on this page so the listed batch can be checked before a research order is reserved.

How should the BPC-157 COA be checked before a research order?

Start with the visible batch number on this product page, open the linked COA, then confirm the compound name, HPLC purity result, mass confirmation, and lot identifier all match the vial being reserved. If a lab needs archival documentation or a batch-specific clarification, contact support before placing the reservation.

BPC-157 Research Product in Canada

Name: BPC-157
Brand: LynxLabs
SKU: BPC-10
Price: 55.00 CAD
Availability: InStock

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide sequence first isolated from human gastric juice. Since the early 1990s it has become one of the most frequently cited recovery peptides in pre-clinical research, with a body of rodent studies exploring tendon, ligament, muscle, gut-lining and vascular response to injury.

At a glance

Peptide class: Synthetic pentadecapeptide / gastric protection fragment
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular formula: C62H98N16O22
Molecular weight: ~1,419.5 g/mol
Appearance (lyophilised): Fine, off-white powder; readily soluble in bacteriostatic water
Primary research themes: Soft-tissue recovery, gastrointestinal lining, angiogenesis, tendon-to-bone models

Why researchers choose our BPC-157

Third-party HPLC-verified purity ≥99.0% on every batch, with the Certificate of Analysis published directly on this page.
Lyophilised under nitrogen in amber glass vials to protect from oxidative and photolytic degradation in transit.
Consistent peptide mass confirmed by ESI-MS alongside HPLC.
Shipped same-day from our Canadian lab with insulated packaging on request for summer transit.

Research-use only

LynxLabs supplies BPC-157 for in-vitro and pre-clinical laboratory research. It is not a drug, food, cosmetic, or dietary supplement and is not sold for human or veterinary use.

Reported mechanisms of action

Rodent and in-vitro literature proposes several converging pathways for BPC-157's activity in injured tissue. The summary below reflects recurring findings in peer-reviewed research; it is not a clinical claim.

Vascular & angiogenic signalling

Multiple rodent models report up-regulation of vascular endothelial growth factor receptor 2 (VEGFR2) and nitric oxide synthase (NOS) expression in tissue treated with BPC-157, which investigators associate with accelerated capillary in-growth into injured tendons and soft tissue.

Growth-factor modulation

Studies describe interactions with the growth-hormone receptor on tendon fibroblasts and downstream modulation of fibroblast growth factor and early growth response protein 1 (EGR-1), correlating with collagen organisation in healing models.

Gastroprotection

Because the parent molecule was originally identified in gastric juice, a substantial share of BPC-157 research examines protection against NSAID-, alcohol- and stress-induced lesions of the gastric mucosa in rodents, with reported effects on dopaminergic and serotonergic signalling.

Stability

Compared with many peptides, BPC-157 is notable for its stability in gastric juice in vitro for extended windows — a property that has driven interest in oral-administration research designs in rodents.

Active research areas

Independent investigators have explored BPC-157 across a wide span of pre-clinical models. Below is a non-exhaustive overview of themes most frequently cited.

Reconstitution, storage & handling

Written for qualified laboratory personnel. Follow your institution's SOP; the guidance below is provided as a general reference for lyophilised research peptides and does not replace site-specific procedures.

Before reconstitution

Store the sealed vial at -20 °C (freezer); short excursions to 2–8 °C during transit are acceptable per stability data on file.
Allow the vial to equilibrate to room temperature for ~20 minutes before opening to reduce condensation on the stopper.
Inspect the lyophilised cake — it should be intact, off-white, with no discoloration. Contact support if the cake appears loose, brown, or fragmented.

Reconstitution

Bacteriostatic water (0.9% benzyl-alcohol) is the standard diluent for multi-dose research workflows.
Introduce diluent slowly down the vial wall, not directly onto the cake, to avoid foaming.
Swirl gently until clear. Do not shake or vortex aggressively.
Once reconstituted, store at 2–8 °C and use within 28 days for best peptide integrity.

After reconstitution

Short-term storage: 2–8 °C, protected from light, up to 28 days in bacteriostatic water.
Long-term storage (lyophilised): -20 °C, desiccated, shelf life 24+ months from manufacture.
Freeze / thaw: Avoid repeated freeze-thaw of reconstituted solution — aliquot at first thaw.

Safety

Use appropriate PPE (gloves, safety glasses, lab coat). Consult the SDS for full hazard and first-aid information. Dispose of sharps and residual solution per your institution's biohazard waste protocol.

Purity, testing & traceability

Every batch of LynxLabs BPC-157 is tested by an independent third-party laboratory. The current batch's Certificate of Analysis is linked above; archival COAs are available on request.

HPLC purity

≥99.0%

Mass confirmation

ESI-MS

Endotoxin

<0.25 EU/mg

Moisture (KF)

<6%

What's on the COA

Batch / lot number matched to the vial label
Manufacture and re-test dates
HPLC chromatogram with peak identification
Mass spectrometry trace and calculated vs. observed mass
Appearance, solubility, water content, and residual solvents

Chain of custody

Batch identifiers are printed on every vial and mirrored on the COA so that laboratory notebooks can cite an unambiguous traceable source.

Canadian research-buyer checklist

Before ordering BPC-157 for a Canadian lab workflow, confirm the product page, lot-specific COA, listed purity result, batch number, and shipping requirements all line up. If any traceability detail is missing, ask support before adding the vial to an order.

Current documentation checkpoint

This is currently the most-visited LynxLabs product landing page, so the above-fold product details and this purity tab are kept aligned around the same buyer checks: research-use-only status, lot traceability, COA availability, purity method, and Canadian shipping context.

How BPC-157 compares to related peptides

Buyers commonly cross-shop BPC-157 with TB-500 (Thymosin Beta-4 fragment) and GHK-Cu. Here is a neutral, research-focused comparison to help structure your protocol selection.

BPC-157 vs. TB-500: BPC-157 literature leans heavily toward tendon, ligament and GI-lining models; TB-500 literature emphasises actin-binding, systemic migration of progenitor cells and cardiac models. Many bench protocols investigate them in parallel rather than as substitutes.
BPC-157 vs. GHK-Cu: GHK-Cu is a copper-binding tripeptide most cited in dermal remodelling and topical-formulation research. BPC-157 sits in the injectable-peptide recovery literature with minimal dermal overlap.
BPC-157 vs. Sermorelin / Ipamorelin: Sermorelin and ipamorelin are GHRH/GHS-R ligands — their research frame is growth-hormone-axis modulation, which is mechanistically distinct from BPC-157's vascular and growth-factor interactions.

Selected literature

A small curated selection of the peer-reviewed research most frequently cited on BPC-157. Provided for research orientation only.

Sikiric P. et al. — Stable gastric pentadecapeptide BPC 157, a novel therapy in gastrointestinal tract (2011)— PubMed
Chang C-H. et al. — BPC 157 accelerates tendon-to-bone healing (2014)— PubMed
Gwyer D. et al. — BPC 157, a pentadecapeptide, healing effects: a review (2019)— PubMed
Seiwerth S. et al. — BPC 157 and blood vessels (2018)— PubMed
Northern Compound — BPC-157 Canada research buyer's guide— Buyer checklist
Northern Compound — angiogenesis peptides and vascular endpoint discipline— Research endpoint guide

Note

External links open on PubMed and are provided for convenience. LynxLabs is not affiliated with the cited authors or institutions.

BPC-157

Verify before you order

Verify the current BPC-157 lot before reservation

Current lot checkpoint

FAQ

About BPC-157